Search
SAB Biotherapeutics Inc
SABSAdd to Watchlist
3.130USD
+0.100+3.30%
Market hours 11/09, 11:15（ET）
284.80MMarket Cap
7.32P/E TTM
Today
+3.30%
5 Days
-6.57%
1 Month
+8.30%
6 Months
-23.84%
Year to Date
-16.31%
1 Year
-2.19%
Key Figures
3.088Open
3.165High
5.37KVolume
7.32P/E TTM
LossP/E Dynamic
--Dividend TTM
0.01%Turnover Ratio
3.030Prev. Close
2.910Low
16.79KTurnover
LossP/E Static
1.35P/B
0.00%Div Yield TTM
-0.28%ROA
5.15052wk High
0.04Volume Ratio
-34.11MNet Profit
90.99MShares
0.4277EPS TTM
0.55Beta
-7.57%ROE
2.44052wk Low
8.42%Amplitude
100.00%Gross Margin
284.80MMarket Cap
1.29Reward/Risk
3.89%Risk Rate
SAB Biotherapeutics Inc's Score
0.00vs previous score
Forecast8.91
Financial Health6.23
Technical5.16
Valuation Dimensions6.89
Institutional Confidence7.00
Risk Assessment4.16
Media Coverage
Coverage Level
Very Low
Very High
Neutral
Analyst Rating
SAB Biotherapeutics Inc Technical Analysis
Technical Indicators
Buy
Summary
Neutral
Moving Average
Sell
SAB Biotherapeutics Inc Latest Earnings Call Transcripts
SAB Bio (SABS) Q3 2026 Earnings Call: SAB-142 Enrollment and Cash Runway
SAB Bio’s Q3 2026 earnings call covered $205 million in cash, higher R&D spending, SAFEGUARD enrollment and SAB-142’s Fast Track designation.
Financial Indicators
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
Earnings
Next reporting date
--
Reporting Period
2026Q3
Earnings / Forecast
-0.24/-0.27
Revenue / Forecast
--/0.00
SAB Biotherapeutics Inc Profile
SectorBiotechnology & Medical Research
Ticker SymbolSABS
Number of employees63
CountryUnited States of America
Ownership
| Shareholders | Proportion |
|---|---|
| Vivo Capital, LLC | 14.94% |
| Commodore Capital LP | 5.76% |
| RA Capital Management, LP | 5.76% |
| Perceptive Advisors LLC | 4.54% |
| Shareholder Types | Proportion |
|---|---|
| Venture Capital | 31.42% |
| Hedge Fund | 27.19% |
| Investment Advisor | 12.26% |
| Private Equity | 6.81% |
Related Instruments
+3.15%
+1.17%
+0.35%
+0.59%
+0.04%
+1.22%
+0.60%
+1.41%
+1.68%
-0.22%
+0.13%
-0.06%
+0.27%
+2.16%
+8.91%
+1.33%
+1.56%
-0.14%
+0.85%
+2.89%Popular Instruments
52199.700
+909.100 (+1.77%)
27743.300
+778.800 (+2.89%)
7520.100
+140.100 (+1.90%)
12797.000
-1.000 (-0.01%)
60440.000
+2298.000 (+3.95%)
6293.000
+152.400 (+2.48%)
86.842
-3.015 (-3.35%)
349.975
+7.605 (+2.22%)
175.160
-11.480 (-6.15%)
4117.220
+51.550 (+1.27%)
FAQs
What is the current price of SAB Biotherapeutics Inc (SABS)?
The current price of SAB Biotherapeutics Inc (SABS) is 3.03.
What is the symbol of SAB Biotherapeutics Inc?
The ticker symbol of SAB Biotherapeutics Inc is SABS.
What is the 52-week high of SAB Biotherapeutics Inc?
The 52-week high of SAB Biotherapeutics Inc is 5.15.
What is the 52-week low of SAB Biotherapeutics Inc?
The 52-week low of SAB Biotherapeutics Inc is 2.44.
What is the market capitalization of SAB Biotherapeutics Inc?
The market capitalization of SAB Biotherapeutics Inc is 275.70M.
Is SAB Biotherapeutics Inc (SABS) currently rated as Buy, Hold, or Sell?
According to analysts, SAB Biotherapeutics Inc (SABS) has an overall rating of Buy, with a price target of 11.64.
What is the Earnings Per Share (EPS TTM) of SAB Biotherapeutics Inc (SABS)?
The Earnings Per Share (EPS TTM) of SAB Biotherapeutics Inc (SABS) is 0.43.